We obtained a total of 397 isolates of
Campylobacterspp. (352 of C. jejuni, 16 of C. coli, and 29 of
C. fetus) from humans, poultry, cattle, and pigs, and examined the susceptibilities of these isolates to 8 antimicrobics, ampicillin (ABPC), gentamicin (GM), erythromycin (EM), imipenem (IPM), tetracycline (TC), chloramphenicol (CP), nalidixic acid (NA), and ciprofloxacin (CPFX). The results obtained were summarized as follows: (i) all
Campylobacterisolates were susceptible to IPM; (ii) almost all isolates except for only a few
C.jejuniisolates were susceptibleto GM and CP; (iii) 27.6 to 75.0% of the isolates in three
Campylobacterspecies were resistant to TC; (iv) 30.1 to 100% and 27.6 to 62.5% of the isolates in these species were resistant to NA and CPFX, respectively, and the cross-resistance to these two antimicrobics was also recognized in most isolates of
C. jejuniand
C. coli.In C. jejuni, 46.2% and 44.6% of human isolates were resistant to NA and CPFX, respectively (high frequency), but 27.8% (NA) and 26.1% (CPFX) of poultry isolates, and 19.0% (NA) and 16.7% (CPFX) of cattle isolates were resistant (low frequency); (v) 43.8% of C. coli isolates were resistant to EM (high frequency), but only 5.4% of C.
jejuniisolates and 3.4% of
C.fetusisolates were resistant (very low frequency); and (vi) all
C. jejuniisolates from cattle were susceptible to ABPC, whereas approximately 20% of the
C. jejuniisolates from humans and poultry were resistant. These findings suggest that
C. jejuniresistant to fluoroquinolones gradually expands, but EM is still effective and available for treatment of human infection by
C. jejuni.
View full abstract